ABSTRACT Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination
of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection …

Introduction: Hepatitis C virus (HCV) infection is a worldwide health problem, whose
management has been revolutionized after the availability of sofosbuvir, a direct-acting …

The treatment for patients infected with hepatitis C virus (HCV) genotype 1 has undergone
major changes with the availability of direct‐acting antivirals. Triple therapy, containing …

Urgent treatments, in any modality, to fight SARS-CoV-2 infections are desired by society in
general, by health professionals, by Estate-leaders and, mainly, by the scientific community …

Nucleos (t) ide analogues play pivotal roles as antiviral, cytotoxic or immunosuppressive
agents. Here, we review recent reports of nucleoside analogues that exhibit broad-spectrum …

Sofosbuvir, a licensed nucleotide analog targeting hepatitis C virus (HCV) RNA-dependent
RNA polymerase (RdRp), has been recently evaluated as a broad anti-Flavivirus lead …

Multiple direct-acting antiviral (DAA)-based regimens are currently approved that provide
one or more interferon-free treatment options for hepatitis C virus (HCV) genotypes (G) 1–6 …

In this review, we summarize the relevant scientific advances that led to the development of
infectious cell culture systems for hepatitis C virus (HCV) with the corresponding challenges …

Introduction: Several HCV polymerase inhibitors are in advanced stages of clinical
development. They are nucleos (t) ide and non-nucleoside analogs. Nucleos (t) ides inhibit …

Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity
between the replication mechanisms of the HCV and the coronavirus. According the limited …